期刊文献+

慢病毒载体定量检测方法的研究进展 被引量:4

Advances in quantification of lentiviral vectors
原文传递
导出
摘要 免疫疗法正在发展成为一种可用于多种恶性肿瘤的有效且侵入性较小的治疗方法。慢病毒载体(Lentiviral vectors,LVs)因其能够稳定地整合相对较大的外源DNA,并且有效地转导分裂细胞和非分裂细胞,已在免疫治疗中显现出巨大潜力。临床应用对慢病毒载体具有较高的质量要求,需要对最终产品进行严格的质量控制以保证其纯度、效力和安全性。其中慢病毒载体的定量检测是产品研发和质控的关键环节之一。文中总结了LVs定量检测的现有方法,包括流式细胞术(Fluorescence activated cell sorter,FACS)、P24酶联免疫法(P24 enzyme-linked immunosorbent assay,P24 ELISA)、实时荧光定量PCR方法 (Real-time fluorescence quantitative polymerase chain reaction,RT-q PCR)、纳米粒子跟踪分析(Nanoparticle tracking analysis,NTA)、可调电阻式脉冲传感(Tunable resistive pulse sensing,TRPS)和病毒计数仪(Virus counter,VC),并对其优缺点进行比较,对发展新的检测方法和存在的挑战进行了展望。 Immunotherapy is becoming an effective and less invasive strategy that can be applied to the treatment of various malignancies. Lentiviral vectors(LVs) have shown great potential in immunotherapy as they can stably integrate relatively large foreign DNA, and effectively transduce dividing and non-dividing cells. Clinical application needs high quality LVs, and therefore strict quality control of the final products is necessary to ensure their purity, efficacy and safety. The quantitative detection of LVs is among the key parts of product development and quality control. In this paper, the existing methods for quantitative detection of LVs are summarized, including fluorescence activated cell sorter(FACS), P24 enzyme-linked immuno sorbent assay(P24 ELISA), real-time fluorescence quantitative polymerase chain reaction(RT-qPCR), nanoparticle tracking analysis(NTA), tunable resistive pulse sensing(TRPS) and virus counter(VC).Their advantages and disadvantages are listed, and future development and challenges are discussed.
作者 陈思琪 张松平 杨延丽 李贺平 王歈 刘幽燕 Siqi Chen;Songping Zhang;Yanli Yang;Heping Li;Yu Wang;Youyan Liu(College of Chemistry and Chemical Engineering,Guangxi University,Nanning 530000,Guangxi,China;State Key Laboratory of Biochemical Engineering,Institute of Process Engineering,Chinese Academy of Sciences,Beijing 100190,China;Beijing YongtaiRuike Biotechnology Co.Ltd.,Beijing 100176,China)
出处 《生物工程学报》 CAS CSCD 北大核心 2021年第7期2283-2292,共10页 Chinese Journal of Biotechnology
基金 国家自然科学基金(No.21821005)资助。
关键词 慢病毒载体 定量 感染性滴度 颗粒分析 lentiviral vectors quantification infective titer particle analysis
  • 相关文献

参考文献5

二级参考文献16

  • 1张敬之,郭歆冰,谢书阳,朱怡文,黄英,王舒,任兆瑞.用慢病毒载体介导产生绿色荧光蛋白(GFP)转基因小鼠[J].自然科学进展,2006,16(5):571-577. 被引量:25
  • 2WU X, LI Y, CRISE B, et al. Transcription start regions in the human genome are favored targets for MLV integration[J]. Science, 2003,300: 1749-1751. 被引量:1
  • 3DEPALMA M, MONTINI E, SANTONIDESIO F R, et al. Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells[J]. Blood, 2005,105(6): 2307-2315. 被引量:1
  • 4SCHRODER A R, SHINN P, CHEN H, et al. HIV-1 integration in the human genome favors active genes and local hotspots[J]. Cell, 2002, 110: 521-529. 被引量:1
  • 5JAKOBSSON J, ERICSON C, JANSSON M, et al. Targeted transgene expression in rat brain using lentiviral vectors[J]. Neurosci Res, 2003, 73(6): 876. 被引量:1
  • 6STEWART S A, OYLOCHOOM D M, PALLISER D, et al. Lentivims-delivered stable gene silencing by RNAi in primary cells[J]. RNA, 2003, 9(4): 493-501. 被引量:1
  • 7MAY C, RIVELLA S, CALLEGARI J, et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin[J]. Nature, 2000, 406 (6791): 82-86. 被引量:1
  • 8HAN X D, LIN C, CHANG J, et al. Fetal gene therapy of α-thalassemia in a mouse model[J]. PNAS, 2007, 104(21): 9007-9011. 被引量:1
  • 9LI W, XIE S Y, GUO X B, et al. A novel transgenic mouse model produced from lentiviral germline integration for the study of β-thalassemia gene therapy[J]. Haematologica, 2008, 93(3): 357-362. 被引量:1
  • 10LOIS C, HONG E J, PEASE S, et al. Germline transmission and tissuespecific expression of transgenes delivered by lentiviral vectors[J]. Science, 2002, 295: 868-872. 被引量:1

共引文献24

同被引文献36

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部